statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mineralys Therapeutics (NASDAQ:MLYS) Given "Outperform" Rating at Lifesci Capital

Lifesci Capital restated their outperform rating on shares of Mineralys Therapeutics (NASDAQ:MLYS - Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Lifesci...

Mineralys Therapeutics (NASDAQ:MLYS) Rating Reiterated by Lifesci Capital

Mineralys Therapeutics (NASDAQ:MLYS  Get Free Report)s stock had its outperform rating restated by analysts at Lifesci Capital in a research report issued on Tuesday...

Mineralys Therapeutics initiated with bullish view at LifeSci Capital

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025...

Mineralys Therapeutics files for $500M mixed shelf offering

Mineralys Therapeutics files for $500M mixed shelf offering...

Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...

MLYS Announces Financial Results for Q4 and Full Year 2023, with Key Clinical Milestones on TrackRelated Stocks: MLYS...

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Commit To Purchase Mineralys Therapeutics At $12.50, Earn 45.9% Annualized Using Options

Investors eyeing a purchase of Mineralys Therapeutics Inc (MLYS) shares, but cautious about paying the going market price of 14.33/share, might benefit from considering selling puts among the...

Mineralys Therapeutics stock jumps on $120M private placement financing

Mineralys Therapeutics stock jumps on $120M private placement financing...

Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Volume	128,254.00
52-Wk High	$16.91
52-Wk Low	$5.85

MLYS Mineralys Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals